Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
The Lancet, 2021•thelancet.com
Vaccines based on the spike glycoprotein of SARS-CoV-2 are being rolled out globally to
control transmission and limit morbidity and mortality due to COVID-19. Current evidence
indicates strong immunogenicity and high short-term efficacy for BNT162b2 (Pfizer–
BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca).
control transmission and limit morbidity and mortality due to COVID-19. Current evidence
indicates strong immunogenicity and high short-term efficacy for BNT162b2 (Pfizer–
BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca).
Vaccines based on the spike glycoprotein of SARS-CoV-2 are being rolled out globally to control transmission and limit morbidity and mortality due to COVID-19. Current evidence indicates strong immunogenicity and high short-term efficacy for BNT162b2 (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca).
thelancet.com